Identification of ERp29 as a biomarker for predicting nasopharyngeal carcinoma response to radiotherapy

  • Authors:
    • Ping Wu
    • Hua Zhang
    • Lin Qi
    • Qingping Tang
    • Yaoyun Tang
    • Zhihai Xie
    • Yunxia Lv
    • Suping Zhao
    • Weihong Jiang
  • View Affiliations

  • Published online on: December 8, 2011     https://doi.org/10.3892/or.2011.1586
  • Pages: 987-994
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Radioresistance continues to be a major problem in the treatment of nasopharyngeal carcinoma (NPC). This study aimed to identify novel proteins associated with NPC radio­resistance. We used a mass spectrometry driven-proteomic strategy to identify novel proteins associated with NPC radio­resistance, and differential proteins were subsequently processed by bio­informatic analysis. As a result, twelve proteins were identified with aberrant expression in radioresistant (RR) NPC tissues compare to radiosensitive (RS) NPC tissues. Among these proteins, ERp29, Mn-SOD, HSP27 and GST ω1 were found to be significantly up-regulated in RR NPC tissues, and ERp29 was selected for further validation. Immunohistochemistry analysis confirmed that ERp29 was overexpressed in RR NPC tissues compared with RS NPC tissues. To prove the role of ERp29 in the induction of NPC radioresistance, ERp29 was down-regulated in the ERp29 enriched NPC cells CNE-1 and 6-10B by specific shRNA. Radiosensitivity was measured using cell proliferation assay and clonogenic survival assay, and cell apoptosis was measured using flow cytometric analysis. We found that ERp29 knockdown attenuated CNE-1 and 6-10B cell radioresistance and enhanced cell apoptosis. These results suggest that ERp29 associates with radioresistance in NPC, and ERp29 could be a potential biomarker for predicting NPC response to radiotherapy.
View Figures
View References

Related Articles

Journal Cover

April 2012
Volume 27 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wu P, Zhang H, Qi L, Tang Q, Tang Y, Xie Z, Lv Y, Zhao S and Jiang W: Identification of ERp29 as a biomarker for predicting nasopharyngeal carcinoma response to radiotherapy. Oncol Rep 27: 987-994, 2012
APA
Wu, P., Zhang, H., Qi, L., Tang, Q., Tang, Y., Xie, Z. ... Jiang, W. (2012). Identification of ERp29 as a biomarker for predicting nasopharyngeal carcinoma response to radiotherapy. Oncology Reports, 27, 987-994. https://doi.org/10.3892/or.2011.1586
MLA
Wu, P., Zhang, H., Qi, L., Tang, Q., Tang, Y., Xie, Z., Lv, Y., Zhao, S., Jiang, W."Identification of ERp29 as a biomarker for predicting nasopharyngeal carcinoma response to radiotherapy". Oncology Reports 27.4 (2012): 987-994.
Chicago
Wu, P., Zhang, H., Qi, L., Tang, Q., Tang, Y., Xie, Z., Lv, Y., Zhao, S., Jiang, W."Identification of ERp29 as a biomarker for predicting nasopharyngeal carcinoma response to radiotherapy". Oncology Reports 27, no. 4 (2012): 987-994. https://doi.org/10.3892/or.2011.1586